S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Tesla hikes price of Model Y after US alters tax credit rule
A gold storm is coming… (Ad)
Route to Super Bowl dangerous for Mexico's avocado haulers
Iraqi currency crash halts after meeting with U.S. official
A gold storm is coming… (Ad)
Europe bans Russian diesel, other oil products over Ukraine
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
A gold storm is coming… (Ad)
Gas prices dip in NJ, around nation as cold weather returns
How will EU ban and West's price cap on Russian diesel work?
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Tesla hikes price of Model Y after US alters tax credit rule
A gold storm is coming… (Ad)
Route to Super Bowl dangerous for Mexico's avocado haulers
Iraqi currency crash halts after meeting with U.S. official
A gold storm is coming… (Ad)
Europe bans Russian diesel, other oil products over Ukraine
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
A gold storm is coming… (Ad)
Gas prices dip in NJ, around nation as cold weather returns
How will EU ban and West's price cap on Russian diesel work?
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Tesla hikes price of Model Y after US alters tax credit rule
A gold storm is coming… (Ad)
Route to Super Bowl dangerous for Mexico's avocado haulers
Iraqi currency crash halts after meeting with U.S. official
A gold storm is coming… (Ad)
Europe bans Russian diesel, other oil products over Ukraine
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
A gold storm is coming… (Ad)
Gas prices dip in NJ, around nation as cold weather returns
How will EU ban and West's price cap on Russian diesel work?
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Tesla hikes price of Model Y after US alters tax credit rule
A gold storm is coming… (Ad)
Route to Super Bowl dangerous for Mexico's avocado haulers
Iraqi currency crash halts after meeting with U.S. official
A gold storm is coming… (Ad)
Europe bans Russian diesel, other oil products over Ukraine
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
A gold storm is coming… (Ad)
Gas prices dip in NJ, around nation as cold weather returns
How will EU ban and West's price cap on Russian diesel work?
NASDAQ:XNCR

Xencor - XNCR Stock Forecast, Price & News

$36.49
+1.35 (+3.84%)
(As of 02/3/2023 12:00 AM ET)
Add
Compare
Today's Range
$34.86
$36.70
50-Day Range
$24.79
$36.49
52-Week Range
$19.35
$36.70
Volume
607,584 shs
Average Volume
359,189 shs
Market Capitalization
$2.19 billion
P/E Ratio
76.02
Dividend Yield
N/A
Price Target
$46.89

Xencor MarketRank™ Forecast

Analyst Rating
Buy
3.09 Rating Score
Upside/​Downside
28.5% Upside
$46.89 Price Target
Short Interest
Bearish
7.49% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.24
Upright™ Environmental Score
News Sentiment
0.74mentions of Xencor in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$100,899 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.61) to ($2.57) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.33 out of 5 stars

Medical Sector

278th out of 1,028 stocks

Pharmaceutical Preparations Industry

127th out of 501 stocks

XNCR stock logo

About Xencor (NASDAQ:XNCR) Stock

Xencor, Inc. is biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.

Receive XNCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xencor and its competitors with MarketBeat's FREE daily newsletter.

XNCR Stock News Headlines

3 Small-Cap Biopharma Stocks that Could See Big Growth in 2023 (XNCR)
Health care stocks are trying to make a comeback and these three small-cap biopharma companies are leading the charge in some ways.
A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
Why Shares of Zencor Rose This Week
A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
Xencor (XNCR) Upgraded to Buy: Here's What You Should Know
Xencor Earnings Preview
Xencor Inc
See More Headlines
Receive XNCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xencor and its competitors with MarketBeat's FREE daily newsletter.

XNCR Company Calendar

Last Earnings
11/07/2022
Today
2/05/2023
Next Earnings (Estimated)
2/22/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:XNCR
Employees
254
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$46.89
High Stock Price Forecast
$58.00
Low Stock Price Forecast
$36.00
Forecasted Upside/Downside
+28.5%
Consensus Rating
Buy
Rating Score (0-4)
3.09
Research Coverage
11 Analysts

Profitability

Net Income
$82.63 million
Pretax Margin
10.44%

Debt

Sales & Book Value

Annual Sales
$296.98 million
Cash Flow
$1.61 per share
Book Value
$12.54 per share

Miscellaneous

Free Float
57,389,000
Market Cap
$2.19 billion
Optionable
Optionable
Beta
0.72

Key Executives

  • Bassil I. DahiyatBassil I. Dahiyat
    President, Chief Executive Officer & Director
  • John J. Kuch
    Chief Financial Officer & Senior Vice President
  • John R. Desjarlais
    Chief Scientific Officer & Senior VP-Research
  • Allen YangAllen Yang
    Chief Medical Officer & Senior Vice President
  • Celia Eckert
    Secretary, Vice President & General Counsel













XNCR Stock - Frequently Asked Questions

Should I buy or sell Xencor stock right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xencor in the last twelve months. There are currently 10 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" XNCR shares.
View XNCR analyst ratings
or view top-rated stocks.

What is Xencor's stock price forecast for 2023?

11 Wall Street research analysts have issued twelve-month price targets for Xencor's stock. Their XNCR share price forecasts range from $36.00 to $58.00. On average, they anticipate the company's share price to reach $46.89 in the next year. This suggests a possible upside of 28.5% from the stock's current price.
View analysts price targets for XNCR
or view top-rated stocks among Wall Street analysts.

How have XNCR shares performed in 2023?

Xencor's stock was trading at $26.04 at the beginning of 2023. Since then, XNCR stock has increased by 40.1% and is now trading at $36.49.
View the best growth stocks for 2023 here
.

When is Xencor's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 22nd 2023.
View our XNCR earnings forecast
.

How were Xencor's earnings last quarter?

Xencor, Inc. (NASDAQ:XNCR) issued its earnings results on Monday, November, 7th. The biopharmaceutical company reported ($0.55) earnings per share for the quarter, beating the consensus estimate of ($0.77) by $0.22. The biopharmaceutical company had revenue of $27.30 million for the quarter, compared to the consensus estimate of $15.33 million. Xencor had a trailing twelve-month return on equity of 4.04% and a net margin of 10.07%.

What is Bassil I. Dahiyat's approval rating as Xencor's CEO?

6 employees have rated Xencor Chief Executive Officer Bassil I. Dahiyat on Glassdoor.com. Bassil I. Dahiyat has an approval rating of 81% among the company's employees.

What other stocks do shareholders of Xencor own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Xencor investors own include Intelsat (I), Bank of America (BAC), Apollo Global Management (APO), Cypress Semiconductor (CY), NVIDIA (NVDA), AbbVie (ABBV), Exelixis (EXEL), Intel (INTC), AMC Entertainment (AMC) and Ciena (CIEN).

What is Xencor's stock symbol?

Xencor trades on the NASDAQ under the ticker symbol "XNCR."

Who are Xencor's major shareholders?

Xencor's stock is owned by a variety of institutional and retail investors. Top institutional investors include EFG Asset Management North America Corp. (0.41%), New York State Common Retirement Fund (0.09%), Assenagon Asset Management S.A. (0.07%), State of Alaska Department of Revenue (0.07%), Yousif Capital Management LLC (0.06%) and Comerica Bank (0.06%). Insiders that own company stock include Allen Yang, Bassil I Dahiyat, Bassil I Dahiyat, Celia Eckert, John J Kuch, John S Stafford III and Ronin Capital, Llc.
View institutional ownership trends
.

How do I buy shares of Xencor?

Shares of XNCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Xencor's stock price today?

One share of XNCR stock can currently be purchased for approximately $36.49.

How much money does Xencor make?

Xencor (NASDAQ:XNCR) has a market capitalization of $2.19 billion and generates $275.11 million in revenue each year. The biopharmaceutical company earns $82.63 million in net income (profit) each year or $0.48 on an earnings per share basis.

How many employees does Xencor have?

The company employs 254 workers across the globe.

How can I contact Xencor?

Xencor's mailing address is 111 WEST LEMON AVENUE, MONROVIA CA, 91016. The official website for the company is www.xencor.com. The biopharmaceutical company can be reached via phone at (626) 305-5900, via email at investors@xencor.com, or via fax at 626-305-0350.

This page (NASDAQ:XNCR) was last updated on 2/5/2023 by MarketBeat.com Staff